Written answers
Wednesday, 15 May 2019
Department of Health
Medicinal Products Regulation
John Brassil (Kerry, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
72. To ask the Minister for Health when a biosimilars policy will be published; and if he will make a statement on the matter. [20811/19]
Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source
My Department and the HSE are engaging in a number of initiatives which will endeavour to lead to better access to medicines for patients, value for the taxpayer and the cost- effective provision of medicines in Ireland.
A public consultation on a National Biosimilar Medicines Policy was undertaken by my Department in 2017. The responses to that consultation and other possible policy levers are being considered by my Department with a view to developing a National Biosimilar Medicines Policy statement which will be published later this year.
At an operational level, the HSE's Acute Hospitals Drugs Management Programme has a biosimilar strategy in place since 2017 which is making considerable progress using a collaborative approach with hospital pharmacists and clinical teams to bring about changes in prescribing practice. In that respect, hospitals are working towards a targeted minimum prescribing rate for biosimilars of 50%.
The HSE is also working on identifying barriers to the prescribing of biosimilars with a specific focus on education and support. It is seeking to increase understanding of biosimilars through targeted presentations to clinicians and hospitals.
The culmination of these initiatives is a greater uptake in the usage of biosimilars and this is evident by hospital dispensing data. For example, the prescribing rate for the biosimilar drug Infliximab has increased from 5% in 2017 to 40% in 2018.
My Department proposes to build on these positive developments and to bring forward a policy statement that would support and complement the many initiatives which are already underway.
No comments